Scholar Rock Holding Corp (SRRK)
NASDAQ:SRRK
Want to see SRRK full AI Analyst Report?
SRRK Stock Chart & Stats
$49.96
-$0.51(-1.26%)
At close: 4:00 PM EST
$49.96
-$0.51(-1.26%)
Day’s Range― - ―
52-Week Range$27.07 - $51.63
Previous CloseN/A
Volume133.12K
Average Volume (3M)1.66M
Market Cap
$5.34B
Enterprise Value$5.10B
Total Cash (Recent Filing)$367.56M
Total Debt (Recent Filing)$108.92M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
May 07, 2026EPS Estimate
-0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.88
Shares Outstanding114,883,095
10 Day Avg. Volume1,531,690
30 Day Avg. Volume1,662,367
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)20.58
Price to Sales (P/S)0.00
P/FCF Ratio-16.81
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.08K
Enterprise Value/Ebitda-13.82
Forecast
1Y Price Target
$58.00Price Target Upside16.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-3.15
Revenue Forecast (FY)$17.60M
Bulls Say, Bears Say
Bulls Say
Clinical Evidence And Market OpportunityStrong late-stage data showing meaningful motor function improvement support the therapy's potential to become a leading treatment for spinal muscular atrophy and drive broad clinical demand.
Commercial Launch ReadinessAn established field team, an expanded specialty pharmacy network, and a large home infusion nurse network position the company to support patient access and initial product rollout effectively.
Financial Support And Revenue AssumptionsSecuring non-dilutive financing and updating the revenue model to reflect dosing dynamics provide funding for commercialization and increase projected peak sales expectations.
Bears Say
Manufacturing Inspection UncertaintyA pending reinspection of a key manufacturing site could yield observations that require formal responses and potentially delay regulatory approval or alter the review pathway.
Market Sentiment And Investor SkepticismNotable short interest signals investor skepticism about near-term prospects and could amplify downside pressure if operational or regulatory setbacks occur.
Reimbursement And Access RiskLimited initial insurance coverage without an established reimbursement code could slow early patient access and hinder near-term sales uptake.
Scholar Rock Holding News
SRRK FAQ
What was Scholar Rock Holding Corp’s price range in the past 12 months?
Scholar Rock Holding Corp lowest stock price was $27.07 and its highest was $51.63 in the past 12 months.
What is Scholar Rock Holding Corp’s market cap?
Scholar Rock Holding Corp’s market cap is $5.34B.
When is Scholar Rock Holding Corp’s upcoming earnings report date?
Scholar Rock Holding Corp’s upcoming earnings report date is May 07, 2026 which is in 9 days.
How were Scholar Rock Holding Corp’s earnings last quarter?
Scholar Rock Holding Corp released its earnings results on Mar 03, 2026. The company reported -$0.88 earnings per share for the quarter, beating the consensus estimate of -$0.89 by $0.01.
Is Scholar Rock Holding Corp overvalued?
According to Wall Street analysts Scholar Rock Holding Corp’s price is currently Undervalued.
Does Scholar Rock Holding Corp pay dividends?
Scholar Rock Holding Corp does not currently pay dividends.
What is Scholar Rock Holding Corp’s EPS estimate?
Scholar Rock Holding Corp’s EPS estimate is -0.8.
How many shares outstanding does Scholar Rock Holding Corp have?
Scholar Rock Holding Corp has 114,883,095 shares outstanding.
What happened to Scholar Rock Holding Corp’s price movement after its last earnings report?
Scholar Rock Holding Corp reported an EPS of -$0.88 in its last earnings report, beating expectations of -$0.89. Following the earnings report the stock price went up 1.909%.
Which hedge fund is a major shareholder of Scholar Rock Holding Corp?
Currently, no hedge funds are holding shares in SRRK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Scholar Rock Holding Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$58.00 (16.09% Upside)
$58.00 (16.09% Upside)
Blogger Sentiment
Bullish
SRRK Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 2.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $11.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.47%
12-Months-Change
Fundamentals
Return on Equity
-145.91%
Trailing 12-Months
Asset Growth
-14.88%
Trailing 12-Months
Company Description
Scholar Rock Holding Corp
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
SRRK Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong forward momentum: focused regulatory engagement with FDA (including a field visit), readiness to resubmit the BLA following an expected reinspection, an advancing clinical pipeline (multiple studies including FSHD and SRK‑439), active commercial build (field team, specialty pharmacy and home infusion networks), and materially strengthened financing optionality (warrant proceeds plus a $550M debt facility). The key negative is continued regulatory and manufacturing risk tied to Catalent’s remediation status, plus high pre‑launch operating spend and potential payer access timing issues. On balance, the highlights—substantive regulatory engagement, concrete mitigation steps (second fill‑finish facility), robust pipeline progress, commercial preparedness, and improved liquidity—outweigh the remaining execution risks.View all SRRK earnings summariesSRRK Stock 12 Month Forecast
Average Price Target
$58.00
▲(16.09% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Viking Therapeutics
―
Xenon
―
Immunovant
―
NewAmsterdam Pharma Company
―
Ownership Overview
21.56% Insiders
29.90% Mutual Funds
0.58% Other Institutional Investors
37.74% Public Companies and
Individual Investors